Search
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
- OPACC
- Nov 4, 2022
- 1 min read
Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments